Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare.
a Health Technology and Services Research , University of Twente , Enschede , The Netherlands.
Pricivel
P
Carrera
a Health Technology and Services Research , University of Twente , Enschede , The Netherlands.
Maarten J
MJ
IJzerman
D000970:Antineoplastic Agents / Q000191:economics; D003362:Cost-Benefit Analysis; D006801:Humans; D009965:Orphan Drug Production / Q000191:economics; D004364:Pharmaceutical Preparations / Q000191:economics*; D057285:Precision Medicine / Q000379:methods*; D013673:Technology Assessment, Biomedical / Q000379:methods*
D000970:Antineoplastic Agents; D004364:Pharmaceutical Preparations
Multiple criteria decision analysis; cost-effectiveness; drug reimbursement; health technology assessment; personalized health care; value-based pricing